INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether Mereo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until April 6, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Mereo securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.          

[Click here for information about joining the class action]  

On July 9, 2025, Mereo and its development partner Ultragenyx Pharmaceutical Inc. issued a press release “announc[ing] that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]”  Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur “around the end of the year.” 

On this news, Mereo’s American Depositary Receipt (“ADR”) price fell $1.25 per share, or 42.52%, to close at $1.69 per share on July 10, 2025. 

Then, on December 29, 2025, Mereo announced that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance.  The press release indicated that neither study met its primary endpoint of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively, despite improved bone mineral density. 

On this news, Mereo’s ADR price fell $2.02 per ADR, or 87.7%, to close at $0.29 per ADR on December 29, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising.  Prior results do not guarantee similar outcomes.

CONTACT: 
Danielle Peyton 
Pomerantz LLP 
dpeyton@pomlaw.com 
646-581-9980 ext. 7980